Catalog No.
Product Name
Application
Product Information
Citations
-
SERT/NET Inhibitor
Amitriptyline is a tricyclic antidepressant that primarily inhibits the serotonin transporter (SERT) and norepinephrine transporter (NET), enhancing synaptic levels of serotonin and norepinephrine. With a Ki value of 3.45 nM for SERT and 13.3 nM for NET, Amitriptyline demonstrates significant antidepressant activity. Additionally, it exhibits agonistic properties at α2A adrenergic and TrkA/TrkB receptors, contributing to its analgesic and neurotrophic effects. Furthermore, Amitriptyline interacts with various receptors, including muscarinic cholinergic and H1 receptors, which may lead to a variety of side effects, while its ability to block sodium channels and hERG potassium channels raises concerns regarding cardiotoxicity. -
V-ATPase Inhibitor
RSC-1255 is a potent and selective inhibitor of Vacuolar H⁺-ATPase (V-ATPase), demonstrating a binding affinity with a Kd of 23 nM. This compound exhibits preferential cytotoxicity towards KRAS-mutant cancer cells, particularly those harboring KRASG13D and KRASG12V mutations. RSC-1255 effectively induces apoptosis while inhibiting lysosomal acidification, autophagy, and macropinocytosis. It serves as a valuable tool for researching KRAS-driven lung and colon cancers. -
ATPase Inhibitor
ATPase-IN-3 is an ATPase inhibitor that demonstrates gastroprotective effects in models of ethanol-induced gastric ulcers. Its mechanism of action involves the modulation of anti-apoptotic pathways through the upregulation of BCL-2 and the activation of tumor suppressor protein P53. This compound is valuable for research applications aimed at investigating gastric ulcer pathophysiology and potential therapeutic interventions. -
Apoptosis Inducer
Rabeprazole-d4 is a deuterated derivative of Rabeprazole, primarily acting as an apoptosis inducer through its irreversible inhibition of gastric H+/K+-ATPase. This second-generation proton pump inhibitor also functions as a uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole-d4 is valuable for research focused on gastric ulcerations and gastroesophageal reflux diseases, facilitating studies on its mechanisms of action and therapeutic potential. -
Calcium Antagonist
Cycleanine is a potent vascular-selective calcium antagonist known for its analgesic, muscle relaxant, and anti-inflammatory properties. This compound exhibits potential anti-ovarian cancer effects by modulating the apoptosis pathway, making it a valuable tool for research in oncology and pain management. Its calcium-blocking mechanism allows for further exploration into vascular functions and related biological systems. -
MDR Reversal Agent
Hydrocinchonine is a multidrug resistance (MDR) reversal agent that functions primarily by inhibiting the activity and expression of P-glycoprotein (P-gp). This inhibition plays a critical role in overcoming drug resistance in cancer treatment. Hydrocinchonine has demonstrated a synergistic apoptotic effect when combined with Paclitaxel in MES-SA/DX5 cells, making it a valuable tool for research aimed at addressing drug-resistant gynecological malignancies, such as uterine sarcoma. -
TRPC6 inhibitor
TRPC6-IN-1 is a Transient Receptor Potential Canonical 6 Channel (TRPC6) inhibitor, with an EC50 of 4.66 μM. - Selamectin is a topical parasiticide and antihelminthic used on dogs and cats to treat and prevent infections of heartworms, fleas, ear mites, sarcoptic mange, and certain types of ticks in dogs as well as prevent heartworms, fleas, ear mites, hookworms, and roundworms in cats.
-
non-ionic emulsifying agent
Polyoxyethylene stearate (POES) is a non-ionic emulsifying agent. -
Calcium channel blocker
Mibefradil is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively. -
Calcium channel blocker
Mibefradil 2Hcl is calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50 values of 2.7 uM and 18.6 uM for T-type and L-type channels respectively. - N-type calcium channel blocker-1 is an orally active analgesic agent which shows high affinity to functionally block N-type calcium channels with an IC50 of 0.7 μM in the IMR32 assay.
-
T-type Ca2+ channel blocker
ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca2+ channel blocker. -
CNT2 Inhibitor
CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2. - Pinaverium Bromide is a spasmolytic agent with low incidence of anticholinergic effects. Pinaverium Bromide is also an antispasmodic.
-
SGLT2 inhibitor
Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. -
TRPV1 antagonist
NJ-17203212 is a novel and selective TRPV1 antagonist, with IC50 of 65 nM and 102 nM for human TRPV1 and rat TRPV1. -
SGLT1/SGLT2 inhibitor
Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor. -
Na+/H+-exchange inhibitor
FR183998 free base is a potent Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively. -
K+ channel blocker?€?
E-4031 dihydrochloride is a selective blocker of KV11.1 (hERG) channels; inhibits the rapid delayed-rectifier K+ current (IKr). -
Na+/H+ exchange inhibitor
Cariporide (HOE-642) is a selective Na+/H+ exchange inhibitor. -
glutamate release inhibitor
Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke. -
Sodium channel blocker
Raxatrigine (GSK1014802) is a novel sodium channel blocker and is an effective anticonvulsant agent. In rats, GSK1014802 (20 - 80 mg/kg p.o.) attenuated the deficit in reversal learning induced by phencyclidine (PCP) in a dose-dependent way, which suggested the potential of GSK1014802 in the treatment of cognitive symptoms of schizophrenia. GSK2 was also a potent inhibitor of human MAO-B with pIC50 value of 7.96 but did not inhibit human MAO-A. -
Istaroxime hydrochloride is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).
-
dihydropyridine calcium entry blocker
Lemildipine is a new dihydropyridine calcium entry blocker. -
Calcium channel blocker
Amlodipine aspartic acid impurity is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties. -
Na+/K+ ATPase modulator
Rostafuroxin (PST-2238) is an ouabain-inhibitor counteracting specific forms of hypertension. - Monocrotaline is a natural 11-membered macrocyclic pyrrolizidine alkaloid used in an animal model of pulmonary hypertension.
